BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada

Completed

Conditions: Central Retinal Vein Occlusion (CRVO)
Age-related Macular Degeneration (AMD)
Diabetic Macular Edema (DME)

Interventions: Drug: Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)

First Posted Date: 2015-10-23

Last Posted Date: 2017-03-21

Lead Sponsor: Bayer

Target Recruit Count: 99

Registration Number: NCT02585401

A Cross-sectional Study for the Determination of the Prevalence of Non-valvular Atrial Fibrillation Among Patients Diagnosed With Hypertension

Completed

Conditions: Atrial Fibrillation
Hypertension

Interventions: Other: Standard of care

First Posted Date: 2015-10-23

Last Posted Date: 2017-05-22

Lead Sponsor: Bayer

Target Recruit Count: 1119

Registration Number: NCT02585076

Extension at 10 Years of the: "Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A."

Completed

Conditions: Hemophilia A

Interventions: Drug: Recombinant Factor VIII (Kogenate FS, BAY14-2222)

First Posted Date: 2015-10-21

Last Posted Date: 2020-11-18

Lead Sponsor: Bayer

Target Recruit Count: 43

Registration Number: NCT02581969

Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: BAY1862864

First Posted Date: 2015-10-21

Last Posted Date: 2020-11-25

Lead Sponsor: Bayer

Target Recruit Count: 21

Registration Number: NCT02581878

Locations: 🇬🇧
Southampton General Hospital, Southampton, Hampshire, United Kingdom
🇸🇪
Skanes Universitetssjukhus, Lund, Sweden
🇬🇧
Royal Marsden NHS Trust (Surrey), Sutton, Surrey, United Kingdom

and more 1 locations

Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye

Phase 4

Completed

Conditions: Macular Degeneration

Interventions: Drug: Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)

First Posted Date: 2015-10-21

Last Posted Date: 2023-11-08

Lead Sponsor: Bayer

Target Recruit Count: 287

Registration Number: NCT02581891

Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME.

Phase 4

Completed

Conditions: Macular Edema

Interventions: Drug: Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)

First Posted Date: 2015-10-21

Last Posted Date: 2018-10-10

Lead Sponsor: Bayer

Target Recruit Count: 560

Registration Number: NCT02581995

Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension)

Completed

Conditions: Hypertension, Pulmonary

Interventions: Drug: Assigned pulmonary hypertension medication

First Posted Date: 2015-10-15

Last Posted Date: 2016-02-26

Lead Sponsor: Bayer

Target Recruit Count: 2691

Registration Number: NCT02576002

A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

Phase 2

Active, not recruiting

Conditions: Solid Tumors Harboring NTRK Fusion

Interventions: Drug: BAY2757556 (Larotrectinib, Vitrakvi)

First Posted Date: 2015-10-15

Last Posted Date: 2025-05-13

Lead Sponsor: Bayer

Target Recruit Count: 215

Registration Number: NCT02576431

Locations: 🇩🇪
Charité Comprehensive Cancer Center (CCCC), Berlin, Germany
🇺🇸
Stanford Cancer Center, Palo Alto, California, United States
🇺🇸
UCLA-Santa Monica Medical Center, Santa Monica, California, United States

and more 95 locations

An Observational Study to Assess Quality of Life and Satisfaction of Young Women (Aged 18-29) Following 6 (±1) Months Using Jaydess as Their Contraceptive Method

Completed

Conditions: Quality of Life

Interventions: Drug: Levonorgestrel (Jaydess, BAY86-5028)

First Posted Date: 2015-10-14

Last Posted Date: 2017-06-29

Lead Sponsor: Bayer

Target Recruit Count: 1039

Registration Number: NCT02574715

A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors

Phase 1

Completed

Conditions: Hemophilia A
Hemophilia B

Interventions: Drug: BAY1093884

First Posted Date: 2015-10-08

Last Posted Date: 2018-10-18

Lead Sponsor: Bayer

Target Recruit Count: 32

Registration Number: NCT02571569

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy